Jeito Capital Co-leads $156 Million Oversubscribed Series B financing in Quell Therapeutics
Paris, France, Nov. 29 (Korea Bizwire) – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led a $156 million oversubscribed Series B financing round in Quell Therapeutics (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by [...]